Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 4, Pages 1416
Publisher
MDPI AG
Online
2020-02-20
DOI
10.3390/ijms21041416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
- (2019) Kengo Takeuchi Frontiers in Physiology
- LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway
- (2019) Chunhua Wei et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
- (2019) Franziska M. Ippen et al. CLINICAL CANCER RESEARCH
- 111OActivity of larotrectinib in TRK fusion lung cancer
- (2019) A Drilon et al. ANNALS OF ONCOLOGY
- Detection of NRG1 Gene Fusions in Solid Tumors
- (2019) Sushma Jonna et al. CLINICAL CANCER RESEARCH
- Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- (2019) Giles W. Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
- (2019) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene of the Month: Neuregulin-1 fusion positive NSCLC (NRG1+ NSCLC)
- (2019) Misako Nagasaka et al. Journal of Thoracic Oncology
- Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)
- (2019) Hongsheng Wang et al. CANCER
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
- (2019) James P. Solomon et al. MODERN PATHOLOGY
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- 1488PDEntrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
- (2019) F G M De Braud et al. ANNALS OF ONCOLOGY
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
- (2019) A. Drilon et al. Journal of Thoracic Oncology
- Selective RET kinase inhibition for patients with RET-altered cancers
- (2018) V Subbiah et al. ANNALS OF ONCOLOGY
- The biology and therapeutic management of melanoma brain metastases
- (2018) Daniel Abate-Daga et al. BIOCHEMICAL PHARMACOLOGY
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1 -Rearranged Non–Small Cell Lung Cancer
- (2018) Ziming Li et al. Journal of Thoracic Oncology
- The incidence of brain metastases in stage IV ROS1 -rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib
- (2018) Tejas Patil et al. Journal of Thoracic Oncology
- Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK -positive non-small-cell lung cancer
- (2018) Makoto Nishio et al. LUNG CANCER
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
- (2018) Alexander Drilon et al. Cancer Discovery
- Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
- (2018) Qingsong Gao et al. Cell Reports
- Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
- (2018) J. Remon et al. Frontiers in Oncology
- Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
- (2018) S Gadgeel et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MET gene fusions in non-small cell lung cancer (NSCLC) in the Chinese population: A multicenter study.
- (2018) Wen xian Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence of EGFR gene fusions in a large cohort of Chinese patients with non-small cell lung cancer (NSCLC).
- (2018) Chunwei Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Thanyanan Reungwetwattana et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling
- (2018) Angel Qin et al. Journal of Thoracic Oncology
- LBA17Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
- (2018) G D Demetri et al. ANNALS OF ONCOLOGY
- PI3K: A master regulator of brain metastasis-promoting macrophages/microglia
- (2018) Raquel Blazquez et al. GLIA
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.
- (2017) Venkataprasanth P. Reddy et al. JOURNAL OF CLINICAL ONCOLOGY
- Hostile takeover: how tumours hijack pre-existing vascular environments to thrive
- (2017) Frank Winkler JOURNAL OF PATHOLOGY
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions
- (2017) S. Rangaraju et al. NEURO-ONCOLOGY
- The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
- (2017) David P. Kodack et al. Science Translational Medicine
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
- (2017) Zoltan Lohinai et al. Scientific Reports
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
- (2016) Solange Peters et al. CANCER TREATMENT REVIEWS
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
- (2016) M. Osswald et al. CLINICAL CANCER RESEARCH
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
- (2015) Gouji Toyokawa et al. CANCER AND METASTASIS REVIEWS
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
- (2015) Vivek Subbiah et al. LUNG CANCER
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
- (2014) G. Chen et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
- (2014) L. Fernandez-Cuesta et al. CLINICAL CANCER RESEARCH
- Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
- (2014) Toshihiko Iuchi et al. International Journal of Clinical Oncology
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer
- (2014) Lin Yang et al. TUMOR BIOLOGY
- CD74-NRG1 Fusions in Lung Adenocarcinoma
- (2014) L. Fernandez-Cuesta et al. Cancer Discovery
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Secretory Breast Carcinoma: Unique, Triple-Negative Carcinoma With a Favorable Prognosis and Characteristic Molecular Expression
- (2011) Pooja Vasudev et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tissue concentration of systemically administered antineoplastic agents in human brain tumors
- (2011) Marshall W. Pitz et al. JOURNAL OF NEURO-ONCOLOGY
- The biology of brain metastases—translation to new therapies
- (2011) April F. Eichler et al. Nature Reviews Clinical Oncology
- A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation
- (2011) C E Tognon et al. ONCOGENE
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
- (2011) Y. J. Yu et al. Science Translational Medicine
- HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors
- (2009) M. Sun et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer
- (2008) Susan C. Pitt et al. SURGERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started